Bristol Myers Squibb will offer Sotyktu (deucravacitinib) at more than 80% off the current list price to eligible, cash-paying U.S. patients, according to a news release published today. The current list price of Sotyktu is $6,828 for a 30-day supply.

This offer builds upon Bristol Myers Squibb’s existing offer of more than 40% off the Eliquis (apixaban) list price. The current list price is $606 for a 30-day supply.

“We are proud to now offer Sotyktu at a lower price via BMS Patient Connect , our new direct-to-patient platform designed to make our innovative medicines more accessible and affordable for patients living with serious conditions,” Christopher Boerner, Ph.D. , board chair and CEO of Bristol Myers Squibb, said in the news release. “We are taking a leading role in r

See Full Page